PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors Scott Kopetz 1, Jayesh Desai 2, Emily Chan 3, J Randolph Hecht 4, Peter J O’Dwyer.

Slides:

Advertisements

Similar presentations

Mr. Tom Jones 123 Sussex Street Anywhere, USA Dear Mr. Jones: It was indeed a pleasure to meet you at last week’s conference. We look.

Advertisements

Certified Silver Master Reviewer, December 2009

1 RIDER and MIRC R… I… D… E… R… Medical Imaging Resource Center.

Efficacy of maraviroc (MVC) administered once-daily or twice-daily with boosted protease inhibitors to treatment-experienced patients S Taylor, 1 J Arribas,

Formatting Book Reference Citations Using APA (6th ed.)

Hospital-Based Careers for Doctoral Scientists Bob Fader, Ph.D. D(ABMM) Section Chief, Microbiology/Virology Scott & White Healthcare Temple, TX

Copyright 2014 Center to Advance Palliative Care. Reproduction by permission only. Palliative care is specialized care for people with serious illness.

Cultural Landscape of the United States and Canada.

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

Architectural Glass Art, Inc. -Health Care- Expanding the Role of Glass in Architecture.

Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,

BRF Begin with BRAF Searching for a target in metastatic melanoma?

Major Events for Segmented Audiences Margaret Miller Assistant Vice President for Alumni Affairs Princeton University.

University Biomedical Informatics Research Training Programs Supported by NLM Biomedical Informatics Training (BIT) Program University of California, Irvine.

September 11, 2001 National Day of Service and Remembrance.

Levothyroxine Suppressive Therapy in Thyroid Cancer R Michael Tuttle, MD Attending Endocrinologist Assistant Professor of Medicine Memorial Sloan Kettering.

Daniel C. Liebler Vanderbilt University School of Medicine Vanderbilt, Tennessee Performance and Optimization of LC-MS/MS Platforms for Unbiased Discovery.

See One, Do One: Creating Geriatric Competencies Assessments for UME/GME Learners: Summary and Action Plan Zaldy S. Tan, MD, MPH Associate Professor, David.

Vanderbilt University NascaBIG ® TBPT Face-to-Face Meeting December 6-7, 2011 Nashville, TN caBIG ® TBPT Face-to-Face Meeting December 6-7, 2011 Vanderbilt.

 Testing ◦ Six different exams in six different subjects at both standard level and higher level  Creativity, Action, Service (CAS) ◦ Perform a minimum.

Desirable Surveillance Network National Prion Disease Pathology Surveillance Center Locations Regularly Performing.

The National Program of Cancer Registries: Enhancing Cancer Incidence Data … Hannah K. Weir, PhD Division of Cancer Prevention and Control Centers for.

Cakes and Other Yummies. Children’s Mercy Hospital (Kansas City, MO) St. Luke’s East Lee’s Summit (MO)

The United States of America. San Francisco, California.

Validation of a 12-Gene Colon Cancer Recurrence Score ® in Stage II Colon Cancer Patients from CALGB 9581 A.P. Venook 1, D. Niedzwiecki 2, M. Lopatin 3,

G. Scott Gazelle, MD, MPH, PhD Director, Partners Radiology Partners Radiology Research Retreat February 26, 2010.

What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.

Geography of the United States the-united-states-of-america ?op=1.

ÖDÜLLÜ TAKILAR AGTA Spectrum Awards™ Background & Past Winners.

Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,

CTOS IS TEN YEARS OLD SARC IS TWO YEARS OLD Happy Birthday, CTOS, SARC.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors.

ASCO 2011 A. Sobrero, 1 M. Peeters, 2 T. Price, 3 Y. Hotko, 4 A. Cervantes, 5 M. Ducreux, 6 T. André, 7 E. Chan, 8 F. Lordick 9 Y. Tian, 10 R. Sidhu 10.

Angiogenic Cytokines Are Increased Prior to Disease Progression In Metastatic Colorectal Cancer Patients Treated With Bevacizumab Scott Kopetz, Paulo M.

How Far We’ve Come Together NIIC Conference.

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results.

By: Callan Mueller Bus111.  - Yobongo is a new way for people to communicate with people nearby  -It is a location based app that takes your position.

A mathematical model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary tumour growth by Jacob G. Scott, David Basanta,

CI-1 Tarceva ® (erlotinib) Tablets in Combination with Gemcitabine as a 1st-line Treatment of Pancreatic Cancer Presentation to the Oncologic Drugs Advisory.

HAWKES LEARNING SYSTEMS Students Matter. Success Counts. Copyright © 2013 by Hawkes Learning Systems/Quant Systems, Inc. All rights reserved. Section 6.3.

Predictive value of skin-toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of 5 clinical.

STATE OF THE WATERWAY Port of S Louisiana, LA 2. Houston, TX 3. New York, NY and NJ 4. Long Beach, CA, 5. New Orleans, LA 6. Beaumont, TX 7.

1 © PD, Incorporated | All Rights Reserved.1 3PDirect – Express Operations August 5, :30 PM.

Rank-Size Rule.

Where Do International Students Work After Graduating? Neil G. Ruiz, GW Center for Law, Economics, and Finance, January 26, 2016.

Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.

What you need to know about Prostate Cancer. Brian McGarry’s Story 1/30/2014 To: DCS Faculty From: Brian McGarry Patty and I received news in the last.

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

Special Seminar Series

Cultural Landscape of the United States and Canada

Brief pain inventory. (Reproduced with permission from the University of Texas MD Anderson Cancer Center, Department of Symptom Research, Houston, TX.

Percentage of secondary schools that had an asthma action plan on file for all students with known asthma Newark Detroit Chicago Philadelphia San Francisco.

Agenda New York Cancer Genomics Research Network Monthly Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting

Which Adjuvant Systemic Treatments Would Medical Oncologists Wish to Receive If They Had Colon Cancer? A Survey of 150 Physicians N Love, MD1; NJ Meropol,

Patients with BRAF mutant CRC should be treated on a clinical trial

New Orleans Hospitality Outlook

Immunotherapy: The Path to Win the War on Cancer?

Culturing Stem Cell Awareness

New CHEST Editorial Board Members

Rank-Size Rule.

New CHEST Editorial Board Members

Meta-analysis of three trials investigating 5-FU and irinotecan.

The 25 U.S. Cities With the Highest Rates of HIV Infection By Daniel Reynolds - Originally published on Advocate.com September :00 AM ET Source.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Epithelial and stromal percentage clusterin staining in normal nonadjacent colonic tissue and matched tumor tissue in 202 patients with stage II colorectal.

Volume 20, Issue 6, Pages (June 2017)

Presentation transcript:

PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors Scott Kopetz 1, Jayesh Desai 2, Emily Chan 3, J Randolph Hecht 4, Peter J O’Dwyer 5, Richard J Lee 6, Keith B Nolop 7, Suman Bhattacharya 8, Leonard Saltz 9 1 The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2 Royal Melbourne Hospital, Parkville, Australia; 3 Vanderbilt-Ingram Cancer Center, Nashville, TN; 4 David Geffen School of Medicine at UCLA, Los Angeles, CA; 5 Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA; 6 Roche, Nutley, NJ; 7 Plexxikon, Berkeley, CA; 8 Genentech, Inc., South San Francisco, CA; 9 Memorial Sloan-Kettering Cancer Center, New York, NY

Kopetz, Desai, et al ASCO 2010 Abs# 3534